ESR1 and breast carcinoma: Simoes et al.48reported that the activity and the frequency of breast cancer stem cell (BCSC) in ER+ patient samples and early and metastatic patient‐derived xenografts (PDXs) were increased after tamoxifen and fulvestrant endocrine therapy.